重组人血管内皮抑制素联合多西他赛及顺铂新辅助化疗治疗晚期上皮性卵巢癌的效果  

Effect of Recombinant Human Endostatin combined with Docetaxel and Cisplatin neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian cancer

作　　者：蔡履娟 应文敏 冯静 骆华春 廖绍光 傅志超 CAI Lü-juan;YING Wen-min;FENG Jing;LUO Hua-chun;LIAO Shao-guang;FU Zhi-chao(Department of Radiotherapy,the 900th Hospital of Joint Service Support Force of PLA,Fujian Province,Fuzhou 350025,China)

机构地区：[1]解放军联勤保障部队第900医院放疗科

出　　处：《中国当代医药》2019年第35期129-133,共5页China Modern Medicine

摘　　要：目的探讨重组人血管内皮抑制素联合多西他赛及顺铂(TP方案)新辅助化疗治疗晚期上皮性卵巢癌的效果。方法选取2012年12月~2015年12月我院初次就诊的76例晚期卵巢癌患者作为研究对象,按照随机数字表法分为观察组和对照组,每组各38例。两组均行术前新辅助化疗,对照组采用TP方案,观察组采用重组人血管内皮抑制素联合TP方案。比较两组的近期化疗不良反应情况、近期疗效、手术情况及远期疗效。结果观察组的血红蛋白下降、白细胞减少、恶心呕吐的不良反应程度低于对照组,差异均有统计学意义(P<0.05);两组化疗后的CA125、肿瘤直径及腹腔积液深度低于化疗前,差异均有统计学意义(P<0.05);观察组>2 cm的残留病灶发生率低于对照组,差异有统计学意义(P<0.05);两组1、3年的总生存率比较,差异无统计学意义(P>0.05);观察组1、3年的无疾病进展生存率高于对照组,差异均有统计学意义(P<0.05)。结论重组人血管内皮抑制素联合TP方案可有效缓解患者的不良反应程度,提高近期疗效及晚期卵巢癌的切净率,延长无疾病进展生存时间。Objective To investigate the effect of Recombinant Human Endostatin combined with Docetaxel and Cisplatin(TP) neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian cancer. Methods A total of 76 patients with advanced epithelial ovarian cancer who first visited our hospital from December 2012 to December 2015 were selected as the study objects, they were divided into observation group and control group according to the random number table method, 38 cases in each group. Both groups treated with neoadjuvant chemotherapy before operation, the control group treated with TP, the observation group treated with Recombinant Human Endostatin combined with TP.The adverse reactions, short-term effect, operation and long-term effect were compared between the two groups. Results The adverse reactions of hemoglobin reduction, leukopenia, nausea and vomiting in the observation group were lower than those in the control group, the differences were statistically significant(P<0.05). CA125, tumor diameter,and depth of peritoneal effusion after chemotherapy were lower in the two groups than before chemotherapy, the differences were statistically significant(P<0.05). The incidence of residual lesions in the observation group>2 cm was lower than that in the control group, the difference was statistically significant(P<0.05). There was no significant difference in the overall survival rate between the two groups at 1 and 3 years(P>0.05). The disease-free survival rate of the observation group at 1 and 3 years were higher than those of the control group, the differences were statistically significant(P<0.05). Conclusion Recombinant Human Endostatin combined with TP can effectively alleviate the degree of adverse reactions in patients, improve the short-term efficacy and the clearance rate of advanced ovarian cancer, and prolong the disease-free survival time.

关 键 词：晚期卵巢癌 重组人血管内皮抑制素 新辅助化疗 疗效 

分 类 号：R737.31[医药卫生—肿瘤]